Agilon Health, Inc.
NYSE:AGLMedical - Care Facilities
+$2.26 today
- Market cap
- $1.52B
- Beta
- 3.04
- P/E (TTM)
- -4.8
- EPS (TTM)
- -$22.50
Volume 0.79M
Average 0.41M
AGL Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Agilon Health, Inc.NYSE: AGL
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents broadly unchanged from a year ago
Cash & equivalents stood at $139.99M at the end of Q1 FY2026, up 1.0% from a year earlier and down 19.4% from the prior quarter. Over 3 fiscal years it compounded at -28.0% a year.
Context
- Cash & equivalents amounted to 9.3% of total assets at the end of Q1 FY2026, up 2.1 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +1.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 173.71M USD
- Year-over-year change
- -10.4%
- 4-year CAGR
- -36.3%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 173.71M | -10.4% |
| FY2024 | 2024-12-31 | 193.86M | +69.6% |
| FY2023 | 2023-12-31 | 114.33M | -75.4% |
| FY2022 | 2022-12-31 | 465.3M | -55.9% |
| FY2021 | 2021-12-31 | 1.05B | — |
Cash & Equivalents vs competitors
How AGL compares with its peers on the latest reported figures
- AGL's Mar 2026 cash & equivalents of $139.99M is the 5th highest of the 10 companies compared; the peer median is $65.39M.
- Its year-over-year change of +1.0% is the 7th highest of 10, against a peer median of +80.4%.
- Cash & equivalents amounts to 9.3% of total assets for AGL, versus a peer median of 30.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $229.2M | +1668.2% | -2.5% | 86.0% | |
| Mar 2026 | $177.91M | +742.2% | +47.1% | 85.3% | |
| Mar 2026 | $175.21M | +80.4% | +5.0% | 66.6% | |
| Mar 2026 | $157.65M | +48.6% | +3.7% | 30.6% | |
| Mar 2026 | $139.99M | +1.0% | -28.0% | 9.3% | |
| Mar 2026 | $65.39M | -4.6% | -24.2% | 41.7% | |
| Mar 2026 | $35.3M | +2994.9% | +394.4% | 5.7% | |
ENGNenGene Holdings Inc. | Apr 2026 | $29.83M | -48.2% | +442.5% | 9.7% |
| Feb 2026 | $25.73M | +134.1% | -15.7% | 17.6% | |
MCTACharming Medical Limited Class A Ordinary Shares | Mar 2025 | $816.77K | -61.2% | — | 15.3% |
| Peer median (excluding AGL) | $65.39M | +80.4% | +4.3% | 30.6% | |
Competitors are the stored peer set for AGL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 1.05B | 465.3M | 114.33M | 193.86M | 173.71M |
| Short-term Investments | 0 | 411.9M | 380.77M | 211.74M | 111.43M |
| Net Receivables | 293.41M | 492.36M | 942.46M | 1.02B | 673.79M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 18.97M | 81.71M | 42.51M | 35.14M | 137.76M |
| Total Current Assets | 1.37B | 1.45B | 1.48B | 1.46B | 1.1B |
| Property, Plant & Equipment (Net) | 20.9M | 31.95M | 40.99M | 36.95M | 25.42M |
| Goodwill | 41.54M | 2.51M | 24.13M | 24.13M | 0 |
| Intangible Assets | 55.4M | 18.45M | 63.77M | 72.77M | 65.73M |
| Long-term Investments | 6.69M | 17.35M | 44.75M | 61.76M | 59.79M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 94.53M | 175.93M | 87.15M | 80.6M | 23.66M |
| Total Non-current Assets | 219.06M | 246.19M | 260.79M | 276.21M | 174.59M |
| Total Assets | 1.59B | 1.7B | 1.74B | 1.73B | 1.27B |
| Account Payables | 348.65M | 478.23M | 968.06M | 1.15B | 1.06B |
| Short-term Debt | 8.31M | 5M | 9.1M | 2.46M | 19.24M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 51.87M | 0 | 0 | 0 |
| Total Current Liabilities | 356.96M | 535.09M | 977.16M | 1.15B | 1.08B |
| Long-term Debt | 43.4M | 38.48M | 32.31M | 34.9M | 15.75M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 86.39M | 74.2M | 59.48M | 69.52M | 50.49M |
| Total Non-current Liabilities | 137.7M | 121.77M | 102.69M | 111.02M | 68.07M |
| Total Liabilities | 494.66M | 656.86M | 1.08B | 1.26B | 1.14B |
| Common Stock | 4M | 4.12M | 4.06M | 4.12M | 4.15M |
| Retained Earnings | (957.68M) | (1.06B) | (1.33B) | (1.59B) | (1.98B) |
| Accumulated OCI | 0 | (5.56M) | (2.3M) | (88K) | 916K |
| Other Stockholders Equity | (0) | 0 | 0 | 0 | 0 |
| Minority Interest | (300K) | (611K) | (818K) | 0 | 0 |
| Total Equity | 1.09B | 1.04B | 661.02M | 470.95M | 126.73M |
| Total Debt | 59.61M | 52.57M | 52.31M | 43.96M | 36.82M |
| Net Debt | (995.21M) | (412.73M) | (62.02M) | (149.9M) | (136.9M) |
Agilon Health, Inc.
NYSE:AGL
Intrinsic Alpha fair value
Locked
Current Price
$90.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.